Mercy Health System Corporation
Mercy Health System Corporation was paid $25.46M by Medicaid between Jan 2018 and Dec 2024, across 387 billing codes. Its largest line is 99283, emergency room visit (moderate) — 7.5% of everything it billed.
33Billing provider infoMERCY HEALTH SYSTEM CORPORATION
JANESVILLE, WI 53548
JANESVILLE, WI 53548
33aNPI1093768962assigned 05/19/2006
33bProvider typeOccupational Therapist
28Total paid$25.46M
24GClaims1,348,429
24DCodes billed387
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Occupational Therapist providers in Wisconsin
Rank by total paid#1 of 43
Median peer was paid$26K
This provider vs. median977×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official MALAS, JOSEPH controls 19+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 224,776 | $4.62M | |
| 2019 | 196,928 | $3.38M | |
| 2020 | 176,626 | $3.27M | |
| 2021 | 199,769 | $3.78M | |
| 2022 | 189,097 | $3.44M | |
| 2023 | 200,151 | $3.83M | |
| 2024incomplete | 161,082 | $3.13M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 7.5% | 32,832 | 28,149 | $1.91M |
| 96361 | Intravenous infusion, hydration; each additional hour | 5.7% | 12,584 | 9,447 | $1.46M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 5.1% | 26,112 | 21,785 | $1.30M |
| 80053 | Comprehensive metabolic panel | 4.6% | 57,918 | 44,579 | $1.17M |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 3.5% | 14,624 | 9,260 | $890K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 3.1% | 9,018 | 8,355 | $788K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 2.7% | 15,183 | 12,376 | $683K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 2.4% | 2,022 | 1,806 | $603K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.3% | 9,836 | 8,763 | $596K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 2.3% | 10,723 | 5,125 | $579K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 2.2% | 14,621 | 12,590 | $569K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 2.2% | 19,863 | 16,569 | $561K |
375 more codes
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 1.9% | 5,692 | $492K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 1.9% | 14,536 | $483K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.8% | 6,968 | $469K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.7% | 6,812 | $424K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 1.6% | 10,181 | $419K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 1.6% | 52,236 | $401K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.4% | 47,812 | $368K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 1.3% | 1,929 | $339K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | 1.2% | 9,746 | $300K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.2% | 7,340 | $300K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.2% | 3,194 | $298K |
| 84443 | Thyroid stimulating hormone (TSH) | 1.2% | 17,747 | $293K |
| 87086 | Culture, bacterial; quantitative colony count, urine | 1.0% | 20,126 | $265K |
| 80048 | Basic metabolic panel (calcium, ionized) | 1.0% | 13,383 | $259K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 3,522 | $246K |
| 87210 | <1% | 9,248 | $231K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 5,750 | $224K |
| 80050 | General health panel | <1% | 7,689 | $215K |
| 80061 | Lipid panel | <1% | 16,775 | $208K |
| 64483 | <1% | 1,131 | $196K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 1,308 | $191K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 6,154 | $187K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 7,608 | $186K |
| 84702 | <1% | 5,162 | $184K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 2,898 | $181K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 7,590 | $172K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 3,041 | $171K |
| 81001 | <1% | 37,549 | $163K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 1,711 | $162K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 4,522 | $155K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 4,543 | $150K |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 5,877 | $146K |
| 85027 | <1% | 24,806 | $139K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 2,836 | $138K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 15,827 | $130K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 2,836 | $128K |
| 87077 | <1% | 7,515 | $127K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 1,902 | $125K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 1,846 | $124K |
| 81025 | <1% | 13,340 | $121K | |
| 84439 | <1% | 7,768 | $120K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 10,469 | $116K |
| 97602 | <1% | 4,555 | $116K | |
| 59025 | Fetal non-stress test | <1% | 1,640 | $115K |
| 87507 | <1% | 349 | $113K | |
| 84484 | <1% | 15,665 | $111K | |
| 82728 | <1% | 4,506 | $108K | |
| 85610 | <1% | 12,418 | $107K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 1,566 | $103K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 2,121 | $100K |
| 76830 | Ultrasound, transvaginal | <1% | 2,706 | $99K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 2,817 | $99K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 1,615 | $96K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 535 | $95K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 8,234 | $86K |
| 83880 | <1% | 4,232 | $86K | |
| 76801 | <1% | 2,223 | $80K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 3,421 | $75K |
| 82607 | <1% | 4,198 | $73K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 1,077 | $68K |
| 82962 | <1% | 14,718 | $66K | |
| 93017 | <1% | 1,600 | $64K | |
| 87186 | <1% | 7,851 | $62K | |
| 87150 | <1% | 1,242 | $62K | |
| 87070 | <1% | 2,563 | $62K | |
| 82043 | <1% | 5,494 | $62K | |
| 83690 | <1% | 11,452 | $59K | |
| 87486 | <1% | 2,021 | $59K | |
| 82950 | <1% | 1,987 | $58K | |
| 83735 | <1% | 11,245 | $54K | |
| 87081 | <1% | 2,133 | $54K | |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | <1% | 31 | $54K |
| 82805 | <1% | 2,484 | $53K | |
| 87581 | <1% | 2,020 | $51K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 2,545 | $51K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 2,109 | $50K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 1,927 | $50K |
| 83605 | <1% | 6,469 | $47K | |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 1,073 | $47K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 1,951 | $46K |
| 86140 | <1% | 5,979 | $46K | |
| 93971 | <1% | 1,571 | $43K | |
| 84145 | <1% | 2,923 | $40K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 247 | $40K |
| 87040 | <1% | 6,523 | $40K | |
| 82075 | <1% | 2,359 | $39K | |
| 82570 | <1% | 7,880 | $39K | |
| 84153 | <1% | 1,517 | $38K | |
| 82746 | <1% | 3,524 | $37K | |
| G0378 | Hospital observation service, per hour | <1% | 10,142 | $37K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 621 | $36K |
| 83540 | <1% | 4,150 | $31K | |
| 93975 | <1% | 829 | $30K | |
| 85379 | <1% | 4,052 | $30K | |
| 96367 | <1% | 1,228 | $30K | |
| 83550 | <1% | 4,084 | $29K | |
| 84703 | <1% | 2,951 | $28K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 4,129 | $28K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 373 | $27K |
| 88141 | <1% | 1,604 | $26K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 502 | $26K |
| 80055 | <1% | 474 | $26K | |
| 71250 | <1% | 909 | $26K | |
| 80069 | <1% | 919 | $26K | |
| 83970 | <1% | 791 | $25K | |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 134 | $25K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 7,531 | $25K |
| 82550 | <1% | 4,589 | $24K | |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 51 | $24K |
| 86850 | <1% | 2,717 | $24K | |
| 86803 | <1% | 1,414 | $24K | |
| 85730 | <1% | 6,040 | $23K | |
| 85014 | <1% | 2,426 | $23K | |
| 70498 | <1% | 268 | $21K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 387 | $19K |
| 74018 | <1% | 1,440 | $19K | |
| 70496 | <1% | 226 | $18K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 13,409 | $18K |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | <1% | 98 | $17K |
| 80076 | <1% | 751 | $17K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 59 | $17K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 19,200 | $17K |
| 70486 | <1% | 478 | $16K | |
| 0002A | <1% | 504 | $16K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 254 | $15K |
| 83655 | <1% | 343 | $15K | |
| 85018 | <1% | 2,742 | $15K | |
| 88342 | <1% | 1,040 | $15K | |
| 0001A | <1% | 535 | $15K | |
| 97162 | <1% | 1,591 | $14K | |
| 82565 | <1% | 1,347 | $14K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 15,439 | $14K |
| 84146 | <1% | 671 | $13K | |
| 87634 | <1% | 171 | $13K | |
| 84156 | <1% | 2,026 | $13K | |
| 71271 | <1% | 277 | $12K | |
| 76642 | <1% | 322 | $12K | |
| 86003 | <1% | 176 | $11K | |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 60 | $11K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 1,611 | $11K |
| 72141 | <1% | 158 | $11K | |
| 85652 | <1% | 4,103 | $11K | |
| 11721 | <1% | 1,238 | $9K | |
| 72100 | <1% | 1,367 | $9K | |
| 81511 | <1% | 51 | $8K | |
| 84112 | <1% | 76 | $8K | |
| 71045 | Radiologic examination, chest; single view | <1% | 10,656 | $8K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 712 | $8K |
| 36415 | Collection of venous blood by venipuncture | <1% | 78,854 | $7K |
| 76770 | <1% | 128 | $7K | |
| 85007 | <1% | 505 | $7K | |
| 43249 | <1% | 26 | $7K | |
| 73630 | <1% | 2,311 | $6K | |
| 76536 | <1% | 159 | $6K | |
| 86900 | <1% | 2,259 | $6K | |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | <1% | 12 | $6K |
| 87536 | <1% | 74 | $6K | |
| 92014 | Ophthalmological services: medical examination and evaluation, comprehensive, established patient | <1% | 586 | $6K |
| 73221 | <1% | 44 | $6K | |
| 86901 | <1% | 2,615 | $6K | |
| 82784 | <1% | 165 | $5K | |
| 86696 | <1% | 217 | $5K | |
| J2704 | Injection, propofol, 10 mg | <1% | 15,203 | $5K |
| 73562 | <1% | 2,059 | $5K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 14,859 | $5K |
| 86592 | <1% | 435 | $5K | |
| 88304 | <1% | 503 | $5K | |
| 95811 | <1% | 27 | $5K | |
| 84481 | <1% | 353 | $5K | |
| 93970 | <1% | 122 | $5K | |
| 90715 | <1% | 1,146 | $4K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 107 | $4K |
| 80164 | <1% | 118 | $4K | |
| 86431 | <1% | 483 | $4K | |
| 86038 | <1% | 318 | $4K | |
| 84100 | <1% | 1,261 | $4K | |
| 83001 | <1% | 153 | $4K | |
| 77080 | <1% | 155 | $4K | |
| 87340 | <1% | 343 | $3K | |
| 86695 | <1% | 216 | $3K | |
| 73030 | <1% | 1,549 | $3K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 47 | $3K |
| 88312 | <1% | 611 | $3K | |
| 95816 | <1% | 29 | $3K | |
| 86200 | <1% | 54 | $3K | |
| 84550 | <1% | 449 | $3K | |
| 72040 | <1% | 146 | $3K | |
| 97166 | <1% | 538 | $3K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 13,815 | $3K |
| 10060 | <1% | 43 | $2K | |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 66 | $2K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 1,777 | $2K |
| 84403 | <1% | 96 | $2K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 7,724 | $2K |
| 93308 | <1% | 18 | $2K | |
| 95819 | <1% | 31 | $2K | |
| 82150 | <1% | 341 | $2K | |
| 83615 | <1% | 510 | $2K | |
| 86618 | <1% | 52 | $2K | |
| 86704 | <1% | 118 | $2K | |
| 83516 | <1% | 115 | $2K | |
| 82553 | <1% | 352 | $2K | |
| 73130 | <1% | 1,113 | $2K | |
| 88313 | <1% | 620 | $2K | |
| 12001 | <1% | 24 | $2K | |
| 99153 | Mod sedat endo service >5yrs | <1% | 235 | $1K |
| C8929 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography | <1% | 26 | $1K |
| 73502 | <1% | 644 | $1K | |
| 73610 | <1% | 1,439 | $1K | |
| 82947 | <1% | 204 | $1K | |
| 80178 | <1% | 13 | $1K | |
| 20610 | <1% | 109 | $1K | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 750 | $1K |
| 73110 | <1% | 802 | $1K | |
| 86706 | <1% | 110 | $1K | |
| 93922 | <1% | 40 | $1K | |
| 86255 | <1% | 80 | $1K | |
| 97163 | <1% | 128 | $1K | |
| 77091 | <1% | 132 | $1K | |
| 87641 | <1% | 13 | $1K | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 13 | $1K |
| 84460 | <1% | 213 | $993.53 | |
| 81003 | <1% | 351 | $929.44 | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 88 | $926.55 |
| 86787 | <1% | 69 | $906.82 | |
| 82951 | <1% | 12 | $903.60 | |
| 82140 | <1% | 50 | $863.45 | |
| 72131 | <1% | 46 | $858.26 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 25,350 | $796.50 |
| 97116 | <1% | 183 | $786.57 | |
| C9290 | Injection, bupivacaine liposome, 1 mg | <1% | 879 | $768.90 |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 187 | $763.98 |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 1,312 | $745.31 |
| 70491 | <1% | 13 | $745.20 | |
| 99152 | <1% | 844 | $729.60 | |
| 82010 | <1% | 49 | $653.05 | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 4,556 | $645.63 |
| 87522 | Neg quan hep c or qual rna | <1% | 16 | $602.17 |
| 83992 | <1% | 29 | $599.43 | |
| 86308 | <1% | 63 | $566.05 | |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | <1% | 2,699 | $528.27 |
| 36591 | <1% | 1,055 | $524.69 | |
| 82272 | <1% | 68 | $493.47 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 1,964 | $491.17 |
| 90686 | <1% | 1,160 | $486.75 | |
| 82040 | <1% | 34 | $454.83 | |
| 87147 | <1% | 106 | $452.39 | |
| 82977 | <1% | 59 | $420.31 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 23,898 | $399.74 |
| 76882 | <1% | 12 | $398.68 | |
| 73080 | <1% | 59 | $386.97 | |
| G0382 | Level 3 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | <1% | 13 | $380.86 |
| 76000 | <1% | 29 | $376.10 | |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 1,297 | $341.48 |
| 88164 | <1% | 29 | $329.92 | |
| 87109 | <1% | 31 | $319.23 | |
| 92004 | Ophthalmological services: medical examination and evaluation, comprehensive, new patient | <1% | 13 | $319.14 |
| G0297 | Low dose ct scan (ldct) for lung cancer screening | <1% | 14 | $302.41 |
| 93880 | <1% | 12 | $286.20 | |
| 96376 | <1% | 4,601 | $285.14 | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 58 | $268.83 |
| 76820 | <1% | 22 | $242.88 | |
| 82785 | <1% | 29 | $221.11 | |
| 77066 | Tomosynthesis, mammo | <1% | 12 | $195.87 |
| 84155 | <1% | 62 | $194.37 | |
| 92610 | <1% | 15 | $165.66 | |
| 84165 | <1% | 17 | $148.20 | |
| 85651 | <1% | 144 | $138.26 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 16,183 | $128.48 |
| 82310 | <1% | 29 | $123.37 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 3,483 | $120.43 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 7,914 | $118.94 |
| 85045 | <1% | 23 | $115.37 | |
| 93325 | <1% | 12 | $115.26 | |
| 84132 | <1% | 36 | $108.30 | |
| G0472 | Hepatitis c antibody screening, for individual at high risk and other covered indication(s) | <1% | 88 | $101.63 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 1,325 | $101.20 |
| 98927 | <1% | 530 | $100.84 | |
| 73140 | <1% | 76 | $95.55 | |
| 87205 | <1% | 40 | $93.05 | |
| L3906 | Wrist hand orthosis, without joints, may include soft interface, straps, custom fabricated, includes fitting and adjustment | <1% | 26 | $89.42 |
| J1815 | Injection, insulin, per 5 units | <1% | 2,192 | $80.24 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,465 | $76.06 |
| 84450 | <1% | 18 | $75.89 | |
| 84520 | <1% | 15 | $61.03 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 3,715 | $56.54 |
| 85048 | <1% | 29 | $55.22 | |
| 82247 | <1% | 19 | $55.12 | |
| G0008 | Administration of influenza virus vaccine | <1% | 1,656 | $53.89 |
| 90732 | <1% | 44 | $52.90 | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 59 | $50.65 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 14,313 | $47.78 |
| S0119 | Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) | <1% | 2,220 | $45.05 |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 391 | $44.25 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 1,817 | $35.98 |
| 90677 | <1% | 38 | $32.62 | |
| 73590 | <1% | 58 | $30.09 | |
| G0009 | Administration of pneumococcal vaccine | <1% | 239 | $28.38 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 4,170 | $27.63 |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 784 | $26.64 |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 316 | $25.71 |
| 99490 | Ccm add 20min | <1% | 355 | $19.52 |
| 90656 | <1% | 33 | $18.74 | |
| 99495 | <1% | 201 | $13.58 | |
| 92226 | <1% | 122 | $11.21 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 6,725 | $7.88 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 8,547 | $7.23 |
| 71101 | <1% | 44 | $4.91 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 117 | $4.87 |
| 92133 | <1% | 40 | $4.56 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 3,750 | $4.32 |
| C1769 | Guide wire | <1% | 299 | $3.75 |
| 92083 | <1% | 27 | $3.42 | |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 379 | $1.50 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 768 | $0.89 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 7,581 | $0.84 |
| 94799 | <1% | 81 | $0.53 | |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 447 | $0.44 |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 286 | $0.37 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 556 | $0.28 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 1,871 | $0.19 |
| 92134 | <1% | 206 | $0.19 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 223 | $0.04 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 3,421 | $0.01 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 377 | $0.01 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 3,202 | $0.01 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 314 | $0.01 |
| J1040 | Injection, methylprednisolone acetate, 80 mg | 0% | 542 | $0.00 |
| J8540 | Dexamethasone, oral, 0.25 mg | 0% | 495 | $0.00 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 2,345 | $0.00 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | 0% | 646 | $0.00 |
| Q9969 | Tc-99m from non-highly enriched uranium source, full cost recovery add-on, per study dose | 0% | 52 | $0.00 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 195 | $0.00 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | 0% | 1,627 | $0.00 |
| J1817 | Insulin for administration through dme (i.e., insulin pump) per 50 units | 0% | 370 | $0.00 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 0% | 437 | $0.00 |
| 73560 | 0% | 30 | $0.00 | |
| V2632 | Posterior chamber intraocular lens | 0% | 93 | $0.00 |
| Q9963 | High osmolar contrast material, 350-399 mg/ml iodine concentration, per ml | 0% | 826 | $0.00 |
| 90480 | 0% | 28 | $0.00 | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | 0% | 44 | $0.00 |
| G8980 | Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting | 0% | 74 | $0.00 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | 0% | 600 | $0.00 |
| J1010 | Injection, methylprednisolone acetate, 1 mg | 0% | 75 | $0.00 |
| 99406 | 0% | 15 | $0.00 | |
| 51798 | 0% | 26 | $0.00 | |
| J3480 | Injection, potassium chloride, per 2 meq | 0% | 25 | $0.00 |
| 72170 | 0% | 18 | $0.00 | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | 0% | 16 | $0.00 |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | 0% | 14 | $0.00 |
| J1940 | Injection, furosemide, up to 20 mg | 0% | 35 | $0.00 |
| S0028 | Injection, famotidine, 20 mg | 0% | 114 | $0.00 |
| S4005 | Interim labor facility global (labor occurring but not resulting in delivery) | 0% | 639 | $0.00 |
| J2550 | Injection, promethazine hcl, up to 50 mg | 0% | 190 | $0.00 |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | 0% | 58 | $0.00 |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | 0% | 292 | $0.00 |
| J0780 | Injection, prochlorperazine, up to 10 mg | 0% | 512 | $0.00 |
| J3475 | Injection, magnesium sulfate, per 500 mg | 0% | 313 | $0.00 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | 0% | 107 | $0.00 |
| J3370 | Injection, vancomycin hcl, 500 mg | 0% | 387 | $0.00 |
| E0110 | Crutches, forearm, includes crutches of various materials, adjustable or fixed, pair, complete with tips and handgrips | 0% | 12 | $0.00 |
| 90662 | 0% | 423 | $0.00 | |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 45 | $0.00 |
| 92202 | 0% | 37 | $0.00 | |
| Q9957 | Injection, perflutren lipid microspheres, per ml | 0% | 102 | $0.00 |
| J1956 | Injection, levofloxacin, 250 mg | 0% | 71 | $0.00 |
| L3260 | Surgical boot/shoe, each | 0% | 62 | $0.00 |
| J1580 | Injection, garamycin, gentamicin, up to 80 mg | 0% | 130 | $0.00 |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | 0% | 15 | $0.00 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 71 | $0.00 |
| J1644 | Injection, heparin sodium, per 1000 units | 0% | 182 | $0.00 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | 0% | 36 | $0.00 |
| 91322 | 0% | 29 | $0.00 | |
| 51701 | 0% | 14 | $0.00 | |
| J0694 | Injection, cefoxitin sodium, 1 gm | 0% | 28 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMALAS, JOSEPH (CFO)
Parent organizationMERCY HEALTH CORPORATION
| Provider | Location | Paid |
|---|---|---|
| Genesis Health System | Davenport, IA | $23.22M |
| Mercy Health System Corporation | Janesville, WI | $13.19M |
| Mercy Health System Corporation | Lake Geneva, WI | $9.39M |
| Mercy Health System Corporation | Janesville, WI | $8.15M |
| Mercy Assisted Care, INC | Janesville, WI | $4.04M |
| Genesis Medical Center, Aledo | Aledo, IL | $3.62M |
| Freeport Memorial Hospital | Freeport, IL | $1.40M |
| Javon Bea Hospital | Rockford, IL | $1.23M |
| Mercy Health System Corporation | Janesville, WI | $1.17M |
| Mercy Assisted Care, INC | Harvard, IL | $601K |
| Mercyhealth Visiting Nurses Association, INC | Rockford, IL | $251K |
| Javon Bea Hospital | Rockford, IL | $174K |
| Genesis Health System | De Witt, IA | $136K |
| Mercy Assisted Care, INC | Janesville, WI | $136K |
| Genesis Health System | Bettendorf, IA | $32K |
| Mercy Assisted Care, INC | Janesville, WI | $12K |
| Mercy Harvard Hospital INC | Harvard, IL | $10K |
| Rockford Health Physicians | Rockford, IL | $9K |
| Mercy Health System Corporation | Janesville, WI | $1K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.